No CrossRef data available.
Article contents
Ivabradine for congenital ectopic tachycardia in newborn
Published online by Cambridge University Press: 18 December 2023
Abstract
Introduction:
Congenital junctional ectopic tachycardia is a rare arrhythmia that occurs in patients without previous cardiac surgery. In this report, we wanted to present a 6-hour-old newborn with congenital junctional ectopic tachycardia resistant to conventional anti-arrhythmic medications, who was successfully treated with ivabradine and amiadarone combination.
Case:
A six-hour-old newborn girl was hospitalised in neonatal ICU because transient tachypnoea of the newborn. She was tachycardic, and supraventricular tachycardia was noticed. There was no answer to the adenosine esmolol treatment; even synchronised direct cardioversion intravenous amiodarone was started. Junctional ectopic tachycardia was diagnosed. We have added propranolol to the treatment and followed patient for 2 days. On the fourth day, junctional ectopic tachycardia rhythm still persisted; therefore, ivabradine treatment was added to the treatment. On the following day, the heart rhythm was slowed to 110/min, and propranolol was stopped; intravenous amiodarone treatment was changed to the oral form. The rhythm turned into sinus; two days after starting ivabradine and oral amiodarone.
Conclusion:
Tachyarrhythmia originating in the atrioventricular node and atrioventricular junction including the bundle of His complex are junctional ectopic tachycardia. Congenital junctional ectopic tachycardia is rare, and it is mostly resistant to the conventional treatment.
Ivabradine is a new anti-arrhythmic agent, used extensively to decrease sinus rate in the treatment of cardiac failure. Ivabradine may be an option for the resistant congenital ectopic tachycardia
- Type
- Brief Report
- Information
- Copyright
- © The Author(s), 2023. Published by Cambridge University Press
References
Tulino, D, Dattilo, G, Tulino, V, Marte, F, Patanè, S. A congenital form of junctional ectopic tachycardia. Int J Cardiol 2010; 145: e54–e56.CrossRefGoogle ScholarPubMed
Kean, AC, Hazle, M, LaPage, MJ, Bromberg, BI. Junctional tachycardia: congenital, acquired, postoperative. In: Macdonald, D II (eds). Clinical Cardiac Electrophysiology in the Young, 2nd edn. Springer, New York, 2016: 157–169.Google Scholar
Josephson, ME. Ectopic rhythms and premature depolarizations. In: Josephson, ME (eds). Josephson’s Clinical Cardiac Electrophysiology: Techniques and Interpretations, 5th edn. Wolters Kluwer Health, Philadelphia, 2016: 163–164.Google Scholar
Al-Ghamdi, S, Al-Fayyadh, MI, Hamilton, RM. Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia. J Cardiovasc Electrophysiol 2013; 24: 822–824.CrossRefGoogle ScholarPubMed
Dieks, JK, Klehs, S, Müller, MJ, Paul, T, Krause, U. Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia. Heart Rhythm 2016; 13: 1297–1302. DOI: 10.1016/j.hrthm.2016.03.015.CrossRefGoogle ScholarPubMed
Kothari, SS, Kidambi, BR, Juneja, R. Ivabradine for congenital junctional ectopic tachycardia in siblings. Ann Pediatr Cardiol 2018; 11: 226–228.CrossRefGoogle ScholarPubMed
Ergul, Y, Ozturk, E, Ozgur, S, Ozyurt, A, Cilsal, E, Guzeltas, A. Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: case studies. Pacing Clin Electrophysiol 2018; 41: 1372–1137.CrossRefGoogle ScholarPubMed